Arcangelo Prete, Edoardo Lanino, Francesco Saglio, Alessandra Biffi, Elisabetta Calore, Maura Faraci, Roberto Rondelli, Claudio Favre, Marco Zecca, Gabriella Casazza, Fulvio Porta, Roberto Luksch, Simone Cesaro, Marco Rabusin, Rosanna Parasole, Rosa Maria Mura, Luca Lo Nigro, Davide Leardini, Daria Pagliara, Franco Locatelli, Franca Fagioli
Despite aggressive multimodal treatment, the outcome of pediatric patients affected by high-risk (HR) neuroblastoma (NB) remains poor. The rational of use of allogeneic hematopoietic stem cell transplantation (allo-HCT) for NB was based on the possible graft versus tumor effect; however, toxicity represents a limitation to its efficacy. We sought to prospectively assess the feasibility and efficacy of allo-HCT using a reduced intensity conditioning regimen in pediatric patients with HR NB in a multicenter phase II trial...
March 7, 2024: Transplantation and cellular therapy